AB668, a novel highly selective protein kinase CK2 inhibitor with a distinct anti-tumor mechanism as compared to CX-4945 and SGC-CK2-1
A. Bancet, R. Frem, F. Jeanneret, A. Mularoni, P. Bazelle, C. Roelants, J.-G. Delcros, J.-F. Guichou, C. Pillet, I. Coste, T. Renno, C. Battail, C. Cochet, T. Lomberget, O. Filhol, I. Krimm
The paper introduces AB668, a selective CK2 inhibitor with a distinct anti-tumor mechanism compared to CX-4945 and SGC-CK2-1, showing apoptotic effects and pathway stimulation in cancer cells.
bioRxiv · Dec 16, 2022 · PreprintBiochemistry